Avilar Therapeutics
- Biotech or pharma, therapeutic R&D
Avilar is pioneering the discovery & development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of degraders that shuttle disease-causing proteins from circulation to the endolysosome where they are degraded. Our current pipeline is targeting high-value, commercially attractive indications in women's health, autoimmune / rare neurology, and cardiometabolic disorders, with both oral and injectable ATACs.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}